As long as the food and drug regulatory authorities approved the use of nifedipine extended-release tablets drug effect is the same, the difference between the drugs is mainly for the weight specifications. Due to the different conditions, each time the dose may be different, according to the doctor’s instructions to choose the appropriate specifications, to avoid breaking or crushing the drug to destroy the shape of the drug, affecting the efficacy of the extended-release tablets. However, it should be noted that nifedipine and other dihydropyridine calcium antagonists should not be abruptly reduced or stopped during use. Caution should be exercised in cases of hypotension, aortic stenosis, hepatic and renal insufficiency. The drug is contraindicated in pregnant women and children. In the use of this drug, jaundice, elevated aminotransferases, headache, palpitations, drop in blood pressure, nausea and other adverse reactions may occur, it is recommended to carry out regular tests for the determination of aminotransferases levels and other checks, and in the event of serious adverse reactions, it is recommended to go to the hospital in a timely manner. Nifedipine and other dihydropyridine calcium antagonists need to be used under the guidance of clinicians, and unauthorized use of drugs is prohibited.